12/23/2009

Astellas Pharma will pay Ambit Biosciences $40 million upfront and as much as $350 million in milestone fees as part of a drug-development collaboration. The partnership covers an acute myeloid leukemia treatment, which is in midstage trials, and other drugs that target an enzyme called FLT3 kinase.

Related Summaries